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Based on the knowledge of the crystal structures of
yeast and Escherichia coli thymidylate kinases (TmpKs)
and the observation that TmpK from E. coli can phos-
phorylate azidothymidine monophosphate (AZT-MP)
much more efficiently than either the yeast or the highly
homologous human enzyme, we have engineered yeast
and human TmpKs to obtain enzymes that have dramat-
ically improved AZT-MP phosphorylation properties.
These modified enzymes have properties that make
them attractive candidates for gene therapeutic ap-
proaches to potentiating the action of AZT as an inhib-
itor of human immunodeficiency virus (HIV) replica-
tion. In particular, insertion of the lid domain of the
bacterial TmpK into the human enzyme results in a pro-
nounced change of the acceptance of AZT-MP such that
it is now phosphorylated even faster than TMP.
One of the main reasons for the less than optimal properties
of nucleoside prodrugs in the treatment of HIV1 infection is
their poor phosphorylation to the active triphosphate form by
cellular enzymes. In the case of 39-azido-39-deoxythymidine
(AZT), the bottleneck in its activation appears to be addition of
the second phosphoryl group to AZT-monophosphate (AZT-MP)
by thymidylate kinase (TmpK) (1, 2). Earlier work suggested
that a specific and unique feature of the highly homologous
yeast and human TmpKs (Fig. 1) is responsible for the low
efficiency of these enzymes in phosphorylating AZT-MP. This is
the fact that an arginine at position X3 of the P-loop (the
GX1X2X3X4GKS(T) motif involved in fixing the a- and b-phos-
phates of ATP (3)) appears to play an important catalytic role
but is mispositioned because of steric hindrance between the
azido group of AZT-MP and the preceding carboxylic acid side
chain of Asp-14 (position X2) (4, 5). A catalytic role was as-
signed to Arg-15 of yeast TmpK based on the observations that
in the structure with the bisubstrate inhibitor P1-(59-adenosyl)-
P5-(59-thymidyl)pentaphosphate (TP5A) this residue interacts
with the g-phosphate of the ATP moiety and that its mutation
to glycine results in a 200-fold decrease of phosphorylation
activity with the natural substrate, dTMP (Table I). Interest-
ingly, TmpK from E. coli has no arginine in its P-loop motif but
rather several arginine residues in its lid region, a flexible
stretch of amino acids that in adenylate kinase becomes or-
dered upon ATP binding (6). One or more of these arginines in
E. coli TmpK were predicted to assume the catalytic role as-
signed to the P-loop arginine of the yeast enzyme. Therefore,
we anticipated that the bacterial TmpK would be less affected
by the presence of the azido group in AZT-MP, and this predic-
tion proved to be correct (7). The crystal structure of the E. coli
enzyme suggested that the role of Arg-15 in the yeast enzyme
is taken over by Arg-153 from the lid region (8). Using this
knowledge we have engineered yeast and human TmpKs to
obtain enzymes that have dramatically improved AZT-MP
phosphorylation properties.
EXPERIMENTAL PROCEDURES
Cloning, Generation of Mutants, and Protein Purification—Yeast
thymidylate kinase was overproduced and purified as described (4). To
facilitate purification, the pJC20 vector was modified (pJC20HisC) such
that a Gly-Ser-(His)6 tail is fused to the C terminus of the authentic
yeast protein. This extension has no influence on the activity of the wild
type protein. All DNA inserts were cloned as NdeI/BamHI-restricted
fragments. Mutants were generated by established polymerase chain
reaction methods, notably by using the gene fusion by overlap extension
strategy. All constructs were verified by automatic DNA sequencing
(Applied Biosystems 373 Sequencer) and data analysis to confirm the
presence of the desired mutation and clone integrity.
Wild type and mutant forms of human thymidylate kinase were
produced as GST-fusion proteins in E. coli strain BL21(DE3) using a
modified expression plasmid pGEX-2T (Amersham Pharmacia Biotech),
which allowed insertion of NdeI/BamHI-restricted fragments into its
multiple cloning site. The coding region of the human gene to be trans-
ferred into this vector was generated by polymerase chain reaction from
a cDNA clone that was a generous gift of Dr. R. A. Sclafani. Expression
of the recombinant protein was induced with 0.5 mM isopropyl-1-thio-
b-D-galactopyranoside at 25 °C overnight. Bacteria were lysed by soni-
cation, and cleared cell lysates were passed over a glutathione-Sepha-
rose column. After extensive washing with phosphate-buffered saline,
the protein was cleaved from the beads with thrombin (using a molar
ratio of about 1:500) for 1–3 h. The cleavage reaction was stopped by the
addition of benzamidine-Sepharose (Amersham Pharmacia Biotech).
The protein thus obtained carries a Gly-Ser-His extension at the N
terminus; it was stored at 220 °C in the presence of 20% glycerol.
Nucleotide sequencing of the entire coding region of human wild type
thymidylate kinase (cDNA clone) revealed several deviations from the
published data (9, 10) (GenBankTM accession numbers X54729 and
L16991) at amino acid positions 31–37, 58, 183/184, and 190/191. The
sequence that we determined for our clone is identical to that published
by Huang et al. (10), with the exception of amino acid 58, which in our
case is Gln instead of Lys in agreement with the publication of Su and
Sclafani (9).
Kinetic Measurements—The catalytic activity of TmpK was meas-
ured at 25 °C using a modified coupled colorimetric assay essentially as
described (11) with the following assay buffer: 100 mM Tris-HCl, pH 7.5,
100 mM KCl, 10 mM MgCl2, 0.5 mM phosphoenol pyruvate, 0.25 mM
NADH, 5 units of lactate dehydrogenase, 4 units of pyruvate kinase, 2
mM ATP, and either 1 mM dTMP or AZT-MP.
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The rationale of our initial design of a yeast TmpK variant
with enhanced AZT-MP activity was to prevent the azido
group-induced P-loop displacement by mutating Asp-14 to a
smaller amino acid. However, all Asp-14 mutant proteins were
catalytically inactive (see Table I). Therefore, we decided to
pursue a new approach that entailed the modification of the
yeast enzyme to mimic the E. coli TmpK, thus, hopefully,
alleviating the detrimental effect of the P-loop mispositioning
by providing catalytic residues from the lid region. The chosen
strategy was to avoid the steric clash between the introduced
arginines in the lid region with the P-loop arginine by first
mutating Arg-15 to glycine. The R15G mutation results in a
200-fold reduced kobs for dTMP but attempts to recover activity
by systematically mutating lid residues (residues 142–146) to
arginines did not increase the dTMP activity appreciably (AZT-
MP activity was not detectable). On close structural compari-
son between the lid regions of the yeast and E. coli TmpKs (8),
we noticed that the lid region of E. coli TmpK is one residue
longer, and that the most promising position for the introduced
arginine (such that it could potentially interact with the
g-phosphate group of ATP) corresponds to the position of Phe-
146. However, the attempt to incorporate this information, by
the simultaneous mutation of Phe-146 to arginine and the
insertion of an alanine residue prior to it, also failed to recover
activity with either dTMP or AZT-MP.
The exact positioning required by the catalytic residues,
which was probably not achieved in our initial efforts of simple
modifications of the yeast lid region, prompted the replacement
of the entire yeast lid region (residues 131–149) by that of the
E. coli lid (residues 138–157) (Fig. 2). The variant that retains
the P-loop arginine exhibits only 4% of wild type activity with
dTMP, with no improvement in AZT-MP phosphorylation.
However, the variant that in addition to the replaced lid has
the P-loop Arg-15 exchanged by a glycine recovers 25% of wild
type activity and, most encouragingly, results in a 400% in-
crease of the AZT-MP phosphorylation rate. This result sug-
gests that the presence of arginines in both P-loop and lid leads
to steric interference but that the loss of activity caused by
removal of Arg-15 can be partially restored by an arginine in
the lid region. In summary, we have created a mutant of yeast
TmpK that phosphorylates AZT-MP four times more efficiently
than wild type, and at the same time the ratio between the kobs
for dTMP and AZT-MP is improved 16-fold.
For the long term aim of gene therapeutic potentiation of
AZT effectiveness, there would be significant advantages from
the use of a modified human enzyme. We therefore extended
the mutational studies to the human enzyme (Table II). Here,
too, mutation of the P-loop carboxylic acid (Asp-15) completely
inactivates the enzyme. Contrary to all expectations arising
from the studies on the yeast enzyme, replacement of Arg-16
(equivalent to Arg-15 in the yeast enzyme) does not lead to a
loss in catalytic activity. At present, we have no experimentally
based explanation for this observation. However, it is possible
TABLE I
Steady state kinetics of yeast thymidylate kinase
Steady state kinetics were measured with the physiological substrate dTMP and the partially activated prodrug AZT-MP. WT, wild type.
kobs for dTMP kobs for AZT-MP
Ratio kobs for dTMP/kobs
for AZT-MP
s21 s21
WT 35 0.175 200




R15G 1 Q142R 1 ,0.01
R15G 1 K143R 1 ,0.01
R15G 1 S144R 0.175 ,0.01
R15G 1 G145R ,0.01 ,0.01
R15G 1 F146R ,0.01 ,0.01
R15G 1 F146[A1R] ,0.01 ,0.01
WT 1 E. coli lida 1.4 ,0.01
R15G 1 E. coli lida 8.75 0.7 12.5
a Residues 131FLSTQDVDNNAEKSGFGDE149 of yeast TmpK were replaced by 138YLDVTPEVGLKRARARGELD157 from E. coli TmpK.
FIG. 1. Structure-based sequence
alignment of human, yeast, and E.
coli TmpK. The P-loop and lid sequences
are marked with stars, and the number-
ing is according to the human enzyme.
Both yeast and human TmpK have an
arginine in the P-loop (shown in bold),
which in the yeast TmpK-TP5A complex
structure (7) was observed to interact
with the phosphate that would corre-
spond to the g-phosphate of ATP. E. coli
TmpK lacks this arginine, having a gly-
cine instead, but compensates with an ar-
ginine that originates from the lid region
(bold). Note the longer lid region of the E.
coli enzyme with respect to the yeast en-
zyme (1 amino acid shorter) and the hu-
man TmpK ( 2 amino acids shorter)
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that it is related to the fact that kobs for the human enzyme is
much lower than for the yeast enzyme (0.7 versus 35 s21),
which is already very slow when compared with other nucleo-
side monophosphate kinases (e.g. 570 s21 for human adenylate
kinase (12). Because the catalytic machinery in both enzymes
appears to be identical, as shown by sequence comparison and
three-dimensional structural determination,2 we speculate
that it is possible that the chemical step (i.e. phosphoryl trans-
fer) is not rate-limiting, but rather another step such as prod-
uct release; so that slowing a relatively rapid chemical step, by
removing the P-loop arginine, might not have any influence on
the overall rate.
More in keeping with expectations arising from the yeast
TmpK data was the fact that introduction of the E. coli lid
region without removing Arg-16 leads to a decrease in catalytic
activity. Most dramatically, the combination of the E. coli lid
with the replacement of Arg-16 by glycine not only restores full
wild type catalytic activity, but it results in a protein that is
more efficient with AZT-MP than with dTMP (for the E. coli
large lid variant, see Table II). The increase in activity with
AZT-MP is approximately 200-fold over wild type. This mutant
thus has properties that are highly attractive for improving the
potency of AZT, because the efficiency of AZT-MP phosphoryl-
ation is improved dramatically with only a minor increase in
dTMP phosphorylation activity. The latter is an important
aspect, because AZTTP must compete with dTTP for HIV re-
verse transcriptase-catalyzed addition to the end of a growing
viral DNA chain.
Interestingly, an increase of AZT-MP phosphorylation with
a concomitant reduced activity for dTMP is achieved by the
F105Y mutant (Table II). The rationale for constructing this
mutant was that in the yeast enzyme, the corresponding
residue (at position 102) is a tyrosine, and its hydroxyl group
interacts with the carboxylate side chain of Asp-14, which
(like Asp-15 in the human enzyme) appears to be an essential
residue for the catalytic mechanism. In the hope for synergy,
we combined our lid modification with the F105Y point mu-
tation (i.e. R16G 1 E. coli large LID 1 F105Y), and in fact,
this variant shows the best catalytic ratio of AZT-MP to
dTMP.
The mutants of TmpK described so far, showing altered
specificity for AZT-MP and dTMP, were produced according to
rational considerations based on comparative structure-func-
tion studies of TmpK from three different sources. Despite
certain gaps in our understanding of the mechanistic features
of TmpK (e.g. the role of Arg-16 in the human enzyme), mu-
tants have been obtained that have almost ideal properties for
enzymes that potentiate the action of AZT, and these are pres-
ently being tested in appropriate cell culture experiments. Fur-
ther unraveling of the details of the mechanism of human
TmpK may lead to the design and construction of mutants that
have an even more pronounced reversal of specificity, i.e. that
can phosphorylate AZT-MP but not dTMP. Earlier attempts to
improve the inhibitory effect of AZT on HIV replication (13), by
transfecting human cells with the herpes simplex virus thymi-
dine kinase (which is several orders of magnitude slower in
AZT-MP phosphorylation than our best human TmpK variant),
have been partially successful, demonstrating the feasibility of
this approach.
Our goal of designing mutants of human TmpK with im-
proved AZT-MP-phosphorylating properties has been criticized
on several grounds (14). One of these is that knowledge of the
structure of the homologous but not identical yeast enzyme
would not be enough to design mutants of the human enzyme
with the desired properties. Although this is a well founded
cautionary note in the absence of evidence to the contrary, the
2 A. Lavie, R. Brundiers, T. Veit, J. Reinstein, I. Schlichting, N.
Ostermann, R. S. Goody, and M. Konrad, manuscript in preparation.
FIG. 2. Arginines that may interact with the g-phosphate of
ATP originate from the P-loop in the case of the human and
yeast enzymes but from the lid region in the case of the E. coli
TmpK. The figure shows an overlay of the yeast TmpK (7) (green) and
E. coli TmpK ( 8) (red) structures, both determined in the presence of
the bisubstrate inhibitor TP5A. The spatial position of the guanidinium
group of Arg-15 of the yeast TmpK and that of Arg-153 of E. coli TmpK
are nearly identical, enabling similar interactions with the third phos-
phate (two conformations were observed for the middle phosphate in
the E. coli-TP5A complex structure).
TABLE II
Steady state kinetics of human TmpK mutants
kobs for
dTMP kobs for AZT-MP





WT 0.73 0.012 61 1
D15X (Ala, Asn, Glu) ,0.001 ,0.001
R16G 1.0 ,0.01
WT 1 E. coli small lida 0.15 0.003 50 0.25
WT 1 E. coli large lidb 0.17 0.002 85 0.17
R16G 1 E. coli small lida 0.7 0.22 3.2 18
R16G 1 E. coli large lidb 1.5 2.14 0.7 178
F105Y 0.17 0.25 0.7 21
R16G 1 E. coli large LIDb 1 F105Y 0.33 0.60 0.55 50
a Residues 145AFGH148 of human TmpK were replaced by 151RARGEL156 from E. coli TmpK.
b Residues 136QLADAAKRGAFGH148 of human TmpK were replaced by 142TPEVGLKRARARGEL156 from E. coli TmpK.
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present work shows that incorporation of knowledge gained
from E. coli TmpK, which can phosphorylate AZT-MP readily,
has indeed allowed our aim to be achieved at the level of
enzyme activity, as predicted by Lavie et al. (7, 8). It is of
interest to note that a similar undertaking with the thymidine/
thymidylate kinase from herpes simplex, in which DNA family
shuffling was used to generate enzymes capable of phosphoryl-
ating AZT more efficiently than the wild type protein, were
considerably less successful than the work presented here in
achieving the desired improvement (15).
Another potential area of application of nucleoside analogs is
that of cancer chemotherapy (reviewed in Ref. 16). The ap-
proach adopted here is to use an analog that is not phospho-
rylated by cellular kinases and to combine this with transfec-
tion with herpes simplex thymidine kinase, which is less
specific in its requirements concerning substrate structure.
Promising results have been obtained in cell culture experi-
ments with the combination of transformation with herpes
simplex thymidine kinase and the open chain guanosine analog
ganciclovir. With the help of the viral kinase, the analog is
phosphorylated to its highly cytotoxic triphosphate. However,
ganciclovir is actually a very poor substrate for herpes simplex
thymidine kinase, and its use may limit the effectiveness of this
approach. The results reported here suggest that a better strat-
egy might be to generate and use mutants of the appropriate
human kinases for the activation of such potentially cytotoxic
prodrugs. This would have the advantage, presumably, of lower
immunogenicity and, judging by the results of mutation of
human Tmpk, potentially higher activity.
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